Supplementary Materials

Supplementary Materials for:

FOXF1 maintains endothelial barrier function and prevents edema after lung injury

Yuqi Cai, Craig Bolte, Tien Le, Chinmayee Goda, Yan Xu, Tanya V. Kalin,* Vladimir V. Kalinichenko*

*Corresponding author. E-mail: vladimir.kalinichenko{at}cchmc.org (V.V.K.); tatiana.kalin{at}cchmc.org (T.V.K.)

This PDF file includes:

  • Fig. S1. Breeding strategy, Tam administration protocol, and analysis of FOXF1 in pulmonary macrophages.
  • Fig. S2. Deletion of Foxf1 from endothelial cells does not influence the histological structure of the liver, heart, and kidney.
  • Fig. S3. FOXF1 is reduced in pulmonary endothelial cells of Tam-treated endFoxf1−/− mice.
  • Fig. S4. Tam treatment reduces the number of FOXF1-positive endothelial cells in endFoxf1−/− lungs.
  • Fig. S5. Cdh5, Flk1, and Pecam-1 mRNAs are present in FACS-sorted endothelial cells.
  • Fig. S6. Transplantation of bone marrow does not affect the lung phenotype of endFoxf1−/− mice.
  • Fig. S7. Deletion of Foxf1 from endothelial cells reduces the abundance of VE-cadherin and S1PR1 in lung tissue.
  • Fig. S8. Experimental protocol for the administration of S1P to BHT-treated heterozygous endFoxf1+/− mice.
  • Fig. S9. S1P does not prevent mortality in Tam-treated homozygous endFoxf1−/− mice.
  • Fig. S10. CYM5442 decreases lung inflammation in LPS-treated endFoxf1+/− mice.
  • Table S1. RNA-seq analysis of FOXF1-deficient lungs.
  • Table S2. TaqMan primers for qPCR.
  • Table S3. Primers used for the ChIP and dual-luciferase assays.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 3.22 MB


Citation: Y. Cai, C. Bolte, T. Le, C. Goda, Y. Xu, T. V. Kalin, V. V. Kalinichenko, FOXF1 maintains endothelial barrier function and prevents edema after lung injury. Sci. Signal. 9, ra40 (2016).

© 2016 American Association for the Advancement of Science